An analysis of patient records suggests that mRNA covid-19 vaccines boost the immune response to cancerous tumours when given ...

The increasing knowledge of barrier tissue-resident memory macrophages and trained innate immunity (TII) will help develop both nontarget-specific and target-specific TII-based vaccine strategies.

Background:Respiratory viruses, including influenza viruses, respiratory syncytial virus (RSV), coronaviruses, and other emerging zoonotic pathogens, remain ...

Light Chain Bioscience, a clinical-stage biotechnology company advancing the next generation of bispecific antibodies to treat cancer, today presented positive results from a Phase 1/1b study of ...

The statements regarding Herpafend have not been evaluated by the Food and Drug Administration (FDA). This product is not ...

Novel combination including eftilagimod alfa (efti) in neoadjuvant setting drives 51.5% tumour hyalinization/fibrosis in patients with soft ...

STAT Wunderkind Sydney Ramirez is revealing the immune system in our nasal passages and working toward better disease ...

Novel combination of efti with KEYTRUDA® and chemotherapy generates strong response rates across all PD-L1 expression levels in first line ...

RNA COVID-19 vaccines — originally developed to protect against the coronavirus — may be providing an additional, unexpected health advantage.

ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, announced today that it will present initial Phase 1 clinical data for ADX ...

BioNTech won’t proceed with further development of its BNT111 cancer vaccine candidate in a specific late-stage refractory ...

The nanoparticle vaccine allowed the mice’s immune system to produce T cells, white blood cells crucial for fighting ...